Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization

eBioMedicine

Volumn 19, Issue , 2017, Pages 107-118

  Dahlke, Christine ^a,i   Kasonta, Rahel ^a,i   Lunemann, Sebastian ^j   Krähling, Verena ^b,k,l   Zinser, Madeleine E ^a   Biedenkopf, Nadine ^k,l   Fehling, Sarah K ^k,l   Ly, My L ^a,i   Rechtien, Anne ^i,j   Stubbe, Hans C ^a,m   Olearo, Flaminia ^a   Borregaard, Saskia ⁿ   Jambrecina, Alen ⁿ   Stahl, Felix ^a   Strecker, Thomas ^k,l   Eickmann, Markus ^k,l   Lütgehetmann, Marc ^a   Spohn, Michael ^j   Schmiedel, Stefan ^a   Lohse, Ansgar W ^a,i   Becker, Stephan ^b,k,l   Addo, Marylyn M ^a,i   Agnandji, Selidji Todagbe ^c   Krishna, Sanjeev ^c,d,e   Kremsner, Peter G ^c,e   Brosnahan, Jessica S ^c,e   Bejon, Philip ^f   Njuguna, Patricia ^f   Siegrist, Claire Anne ^g   Huttner, Angela ^g   Kieny, Marie Paule ^h   Modjarrad, Kayvon ^h   Moorthy, Vasee ^h   Fast, Patricia ^h   Savarese, Barbara ^h   Lapujade, Olivier ^h   more..

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Institute for Virology   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^e Centre de Recherches Medicales de Lambaréné Lambarene   (Germany)

^f KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^g GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^h WORLD HEALTH ORGANIZATION   (Switzerland)

ⁱ German Center for Infection Research (DZIF)   (Germany)

^j LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

^k PHILIPPS UNIVERSITY MARBURG   (Germany)

^l UNIVERSITY HOSPITAL MARBURG   (Germany)

^m LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

ⁿ Clinical Trial Center North GmbH   (Germany)

more..

Author keywords

Cytokines; Ebola vaccine; Humoral and cell mediated immune responses; Phase I study; rVSV ZEBOV; T cell responses

Indexed keywords

CD19 ANTIGEN; CD24 ANTIGEN; CD38 ANTIGEN; EBOLA VACCINE; GAMMA INTERFERON; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 7; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; NEUTRALIZING ANTIBODY; RECOMBINANT VESICULAR STOMATITIS VIRUS VECTORED EBOLA VACCINE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; BACTERIUM ANTIBODY; CYTOKINE; GLYCOPROTEIN; PEPTIDE; VIRAL PROTEIN; VIRUS ANTIBODY;

ADULT; ARTHRALGIA; ARTHRITIS; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOKINE RELEASE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOMODULATION; LOW DRUG DOSE; LYMPHOCYTOPENIA; MALE; MIDDLE AGED; MYALGIA; NORMAL HUMAN; OPEN STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; T LYMPHOCYTE; TH1 TH2 BALANCE; VACCINE IMMUNOGENICITY; VIREMIA; VIRUS NEUTRALIZATION; YOUNG ADULT; BLOOD; CLINICAL TRIAL; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; GENETICS; IMMUNOLOGY; VESICULAR STOMATITIS INDIANA VIRUS;

ADULT; ANTIBODIES, BACTERIAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; B-LYMPHOCYTES; CYTOKINES; EBOLA VACCINES; EBOLAVIRUS; FEMALE; GLYCOPROTEINS; HEMORRHAGIC FEVER, EBOLA; HUMANS; IMMUNIZATION; MALE; MIDDLE AGED; PEPTIDES; T-LYMPHOCYTES; VESICULAR STOMATITIS INDIANA VIRUS; VIRAL PROTEINS; YOUNG ADULT;

EID: 85018651530     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2017.03.045     Document Type: Article

References (33)

1. Agnandji, S.T., Huttner, A., Zinser, M.E., Njuguna, P., Dahlke, C., Fernandes, J.F., Yerly, S., Dayer, J.A., Kraehling, V., Kasonta, R., Adegnika, A.A., Altfeld, M., Auderset, F., Bache, E.B., Biedenkopf, N., Borregaard, S., Brosnahan, J.S., Burrow, R., Combescure, C., Desmeules, J., Eickmann, M., Fehling, S.K., Finckh, A., Goncalves, A.R., Grobusch, M.P., Hooper, J., Jambrecina, A., Kabwende, A.L., Kaya, G., Kimani, D., Lell, B., Lemaitre, B., Lohse, A.W., Massinga-Loembe, M., Matthey, A., Mordmuller, B., Nolting, A., Ogwang, C., Ramharter, M., Schmidt-Chanasit, J., Schmiedel, S., Silvera, P., Stahl, F.R., Staines, H.M., Strecker, T., Stubbe, H.C., Tsofa, B., Zaki, S., Fast, P., Moorthy, V., Kaiser, L., Krishna, S., Becker, S., Kieny, M.P., Bejon, P., Kremsner, P.G., Addo, M.M., Siegrist, C.A., Phase 1 trials of rVSV Ebola vaccine in Africa and Europe. N. Engl. J. Med. 374 (2016), 1647–1660.
2. Blom, K., Braun, M., Ivarsson, M.A., Gonzalez, V.D., Falconer, K., Moll, M., Ljunggren, H.G., Michaelsson, J., Sandberg, J.K., Temporal dynamics of the primary human T cell response to yellow fever virus 17D as it matures from an effector- to a memory-type response. J. Immunol. 190 (2013), 2150–2158.
3. Dahlke, C., Lunemann, S., Kasonta, R., Kreuels, B., Schmiedel, S., Ly, M.L., Fehling, S.K., Strecker, T., Becker, S., Altfeld, M., Sow, A., Lohse, A.W., Munoz-Fontela, C., Addo, M.M., Comprehensive characterization of cellular immune responses following Ebola virus infection. J Infect Dis. 215:2 (2017), 287–292, 10.1093/infdis/jiw508 (PMID: 27799354).
4. De Santis, O., Audran, R., Pothin, E., Warpelin-Decrausaz, L., Vallotton, L., Wuerzner, G., Cochet, C., Estoppey, D., Steiner-Monard, V., Lonchampt, S., Thierry, A.C., Mayor, C., Bailer, R.T., Mbaya, O.T., Zhou, Y., Ploquin, A., Sullivan, N.J., Graham, B.S., Roman, F., De Ryck, I., Ballou, W.R., Kieny, M.P., Moorthy, V., Spertini, F., Genton, B., Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. Lancet Infect. Dis. 16 (2016), 311–320.
5. De Wit, E., Marzi, A., Bushmaker, T., Brining, D., Scott, D., Richt, J.A., Geisbert, T.W., Feldmann, H., Safety of recombinant VSV-Ebola virus vaccine vector in pigs. Emerg. Infect. Dis. 21 (2015), 702–704.
6. Farooq, F., Beck, K., Paolino, K.M., Phillips, R., Waters, N.C., Regules, J.A., Bergmann-Leitner, E.S., Circulating follicular T helper cells and cytokine profile in humans following vaccination with the rVSV-ZEBOV Ebola vaccine. Sci. Rep., 6, 2016, 27944.
7. Feldmann, H., Jones, S.M., Daddario-Dicaprio, K.M., Geisbert, J.B., Stroher, U., Grolla, A., Bray, M., Fritz, E.A., Fernando, L., Feldmann, F., Hensley, L.E., Geisbert, T.W., Effective post-exposure treatment of Ebola infection. PLoS Pathog., 3, 2007, e2.
8. Geisbert, T.W., Daddario-Dicaprio, K.M., Geisbert, J.B., Reed, D.S., Feldmann, F., Grolla, A., Stroher, U., Fritz, E.A., Hensley, L.E., Jones, S.M., Feldmann, H., Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine 26 (2008), 6894–6900.
9. Geisbert, T.W., Feldmann, H., Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J. Infect. Dis. 204:Suppl. 3 (2011), S1075–S1081.
10. Gupta, M., Greer, P., Mahanty, S., Shieh, W.J., Zaki, S.R., Ahmed, R., Rollin, P.E., CD8-mediated protection against Ebola virus infection is perforin dependent. J. Immunol. 174 (2005), 4198–4202.
11. Henao-Restrepo, A.M., Camacho, A., Longini, I.M., Watson, C.H., Edmunds, W.J., Egger, M., Carroll, M.W., Dean, N.E., Diatta, I., Doumbia, M., Draguez, B., Duraffour, S., Enwere, G., Grais, R., Gunther, S., Gsell, P.S., Hossmann, S., Watle, S.V., Konde, M.K., Keita, S., Kone, S., Kuisma, E., Levine, M.M., Mandal, S., Mauget, T., Norheim, G., Riveros, X., Soumah, A., Trelle, S., Vicari, A.S., Rottingen, J.A., Kieny, M.P., Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!). Lancet 389:10068 (2017), 505–518, 10.1016/S0140-6736(16)32621-6 (Epub 2016 Dec 23.PMID:28017403).
12. Jones, S.M., Feldmann, H., Stroher, U., Geisbert, J.B., Fernando, L., Grolla, A., Klenk, H.D., Sullivan, N.J., Volchkov, V.E., Fritz, E.A., Daddario, K.M., Hensley, L.E., Jahrling, P.B., Geisbert, T.W., Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med. 11 (2005), 786–790.
13. Jones, S.M., Stroher, U., Fernando, L., Qiu, X., Alimonti, J., Melito, P., Bray, M., Klenk, H.D., Feldmann, H., Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever. J Infect Dis 196:Suppl. 2 (2007), S404–S412.
14. Kang, T.H., Bae, H.C., Kim, S.H., Seo, S.H., Son, S.W., Choi, E.Y., Seong, S.Y., Kim, T.W., Modification of dendritic cells with interferon-gamma-inducible protein-10 gene to enhance vaccine potency. J. Gene Med. 11 (2009), 889–898.
15. Khurana, S., Fuentes, S., Coyle, E.M., Ravichandran, S., Davey, R.T., Jr. & Beigel, J. H., Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies. Nat. Med. 22 (2016), 1439–1447.
16. Krahling, V., Becker, D., Rohde, C., Eickmann, M., Eroglu, Y., Herwig, A., Kerber, R., Kowalski, K., Vergara-Alert, J., Becker, S., Development of an antibody capture ELISA using inactivated Ebola Zaire Makona virus. Med. Microbiol. Immunol. 205 (2016), 173–183.
17. Lai, L., Davey, R., Beck, A., Xu, Y., Suffredini, A.F., Palmore, T., Kabbani, S., Rogers, S., Kobinger, G., Alimonti, J., Link, C.J. Jr., Rubinson, L., Stroher, U., Wolcott, M., Dorman, W., Uyeki, T.M., Feldmann, H., Lane, H.C., Mulligan, M.J., Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick. JAMA 313 (2015), 1249–1255.
18. Marzi, A., Engelmann, F., Feldmann, F., Haberthur, K., Shupert, W.L., Brining, D., Scott, D.P., Geisbert, T.W., Kawaoka, Y., Katze, M.G., Feldmann, H., Messaoudi, I., Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 1893–1898.
19. Marzi, A., Hanley, P.W., Haddock, E., Martellaro, C., Kobinger, G., Feldmann, H., Efficacy of vesicular stomatitis virus-Ebola virus postexposure treatment in rhesus macaques infected with Ebola virus Makona. J. Infect. Dis. 214 (2016), S360–s366.
20. Marzi, A., Robertson, S.J., Haddock, E., Feldmann, F., Hanley, P.W., Scott, D.P., Strong, J.E., Kobinger, G., Best, S.M., Feldmann, H., EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain. Science 349 (2015), 739–742.
21. Mcelroy, A.K., Akondy, R.S., Davis, C.W., Ellebedy, A.H., Mehta, A.K., Kraft, C.S., Lyon, G.M., Ribner, B.S., Varkey, J., Sidney, J., Sette, A., Campbell, S., Stroher, U., Damon, I., Nichol, S.T., Spiropoulou, C.F., Ahmed, R., Human Ebola virus infection results in substantial immune activation. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 4719–4724.
22. Meyer, M., Garron, T., Lubaki, N.M., Mire, C.E., Fenton, K.A., Klages, C., Olinger, G.G., Geisbert, T.W., Collins, P.L., Bukreyev, A., Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses. J. Clin. Invest. 125 (2015), 3241–3255.
23. Miller, J.D., Van Der Most, R.G., Akondy, R.S., Glidewell, J.T., Albott, S., Masopust, D., Murali-Krishna, K., Mahar, P.L., Edupuganti, S., Lalor, S., Germon, S., Del Rio, C., Mulligan, M.J., Staprans, S.I., Altman, J.D., Feinberg, M.B., Ahmed, R., Human effector and memory CD8 + T cell responses to smallpox and yellow fever vaccines. Immunity 28 (2008), 710–722.
24. Nakaya, H.I., Wrammert, J., Lee, E.K., Racioppi, L., Marie-Kunze, S., Haining, W.N., Means, A.R., Kasturi, S.P., Khan, N., Li, G. M., Mccausland, M., Kanchan, V., Kokko, K. E., Li, S., Elbein, R., Mehta, A. K., Aderem, A., Subbarao, K., Ahmed, R. & Pulendran, B., Systems biology of vaccination for seasonal influenza in humans. Nat. Immunol. 12 (2011), 786–795.
25. Pavot, V., Ebola virus vaccines: where do we stand?. Clin. Immunol. 173 (2016), 44–49.
26. Qiu, X., Fernando, L., Alimonti, J.B., Melito, P.L., Feldmann, F., Dick, D., Stroher, U., Feldmann, H., Jones, S.M., Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses. PLoS One, 4, 2009, e5547.
27. Regules, J.A., Beigel, J.H., Paolino, K.M., Voell, J., Castellano, A.R., Hu, Z., Munoz, P., Moon, J.E., Ruck, R.C., Bennett, J.W., Twomey, P.S., Gutierrez, R.L., Remich, S.A., Hack, H.R., Wisniewski, M.L., Josleyn, M.D., Kwilas, S.A., Van Deusen, N., Mbaya, O.T., Zhou, Y., Stanley, D.A., Jing, W., Smith, K.S., Shi, M., Ledgerwood, J.E., Graham, B.S., Sullivan, N.J., Jagodzinski, L.L., Peel, S.A., Alimonti, J.B., Hooper, J.W., Silvera, P.M., Martin, B.K., Monath, T.P., Ramsey, W.J., Link, C.J., Lane, H.C., Michael, N.L., Davey, R.T. Jr., Thomas, S.J., A recombinant vesicular stomatitis virus Ebola vaccine. N. Engl. J. Med. 376 (2017), 330–341.
28. Ruibal, P., Oestereich, L., Ludtke, A., Becker-Ziaja, B., Wozniak, D.M., Kerber, R., Korva, M., Cabeza-Cabrerizo, M., Bore, J.A., Koundouno, F.R., Duraffour, S., Weller, R., Thorenz, A., Cimini, E., Viola, D., Agrati, C., Repits, J., Afrough, B., Cowley, L.A., Ngabo, D., Hinzmann, J., Mertens, M., Vitoriano, I., Logue, C.H., Boettcher, J.P., Pallasch, E., Sachse, A., Bah, A., Nitzsche, K., Kuisma, E., Michel, J., Holm, T., Zekeng, E.G., Garcia-Dorival, I., Wolfel, R., Stoecker, K., Fleischmann, E., Strecker, T., Di Caro, A., Avsic-Zupanc, T., Kurth, A., Meschi, S., Mely, S., Newman, E., Bocquin, A., Kis, Z., Kelterbaum, A., Molkenthin, P., Carletti, F., Portmann, J., Wolff, S., Castilletti, C., Schudt, G., Fizet, A., Ottowell, L.J., Herker, E., Jacobs, T., Kretschmer, B., Severi, E., Ouedraogo, N., Lago, M., Negredo, A., Franco, L., Anda, P., Schmiedel, S., Kreuels, B., Wichmann, D., Addo, M.M., Lohse, A.W., De Clerck, H., Nanclares, C., Jonckheere, S., Van Herp, M., Sprecher, A., Xiaojiang, G., Carrington, M., Miranda, O., Castro, C.M., Gabriel, M., Drury, P., Formenty, P., Diallo, B., Koivogui, L., Magassouba, N., Carroll, M.W., Gunther, S., Munoz-Fontela, C., Unique human immune signature of Ebola virus disease in Guinea. Nature 533 (2016), 100–104.
29. Sullivan, N.J., Geisbert, T.W., Geisbert, J.B., Xu, L., Yang, Z. Y., Roederer, M., Koup, R. A., Jahrling, P. B. & Nabel, G. J., Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424 (2003), 681–684.
30. Sullivan, N.J., Martin, J.E., Graham, B.S., Nabel, G.J., Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat. Rev. Microbiol. 7 (2009), 393–400.
31. Wilson, J.A., Hart, M.K., Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein. J. Virol. 75 (2001), 2660–2664.
32. Wong, G., Audet, J., Fernando, L., Fausther-Bovendo, H., Alimonti, J.B., Kobinger, G.P., Qiu, X., Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents. Vaccine 32 (2014), 5722–5729.
33. Wong, G., Richardson, J.S., Pillet, S., Patel, A., Qiu, X., Alimonti, J., Hogan, J., Zhang, Y., Takada, A., Feldmann, H., Kobinger, G.P., Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates. Sci. Transl. Med., 4, 2012 (158ra146).